Madhusoodanan Subramoniam, Bogunovic Olivera
Peninsula Hospital Center, New York, NY, USA.
Am J Alzheimers Dis Other Demen. 2006 Jun-Jul;21(3):169-74. doi: 10.1177/1533317506289257.
The objective of this study was to collect data on outcomes obtained when switching elderly nursing home residents with dementia from risperidone to quetiapine. Medical records were reviewed to identify dementia patients switched from risperidone to quetiapine. Clinical Global Impressions (CGI) scores assigned retrospectively (at switch and weeks 4-6) assessed treatment. Data from 15 men and 52 women (mean age, 82.8 years) were evaluated. The mean daily dose of risperidone at switch was 1.42 mg. Switching was abrupt in all but 2 patients. The mean daily dose of quetiapine after the switch was 87.3 mg. After the switch, the CGI Severity of Illness score remained unchanged, but the CGI Global Improvement score was positive. Fourteen patients reported somnolence; 3 patients discontinued quetiapine. Most patients in this study were switched from risperidone to quetiapine with no worsening of clinical status.
本研究的目的是收集有关老年痴呆症疗养院居民从利培酮换用喹硫平后的治疗结果数据。查阅病历以确定从利培酮换用喹硫平的痴呆症患者。回顾性评定（换药时以及第4至6周）的临床总体印象（CGI）评分用于评估治疗情况。对15名男性和52名女性（平均年龄82.8岁）的数据进行了评估。换药时利培酮的平均日剂量为1.42毫克。除2名患者外，所有患者的换药过程均为突然换药。换药后喹硫平的平均日剂量为87.3毫克。换药后，CGI疾病严重程度评分保持不变，但CGI总体改善评分为阳性。14名患者报告有嗜睡症状；3名患者停用了喹硫平。本研究中的大多数患者从利培酮换用喹硫平后临床状况并未恶化。
